THE POMPE DISEASE

Suggested Readings by Topic

Introduction

Alglucosidase alfa (Lumizyme) PI. Genzyme Corporation; 2020. https://www.lumizyme.com/-/media/ems/conditions/rarediseases/brands/lumizyme-new/site-pdf/lumizyme.pdf

Ausems MG, et al. A diagnostic protocol for adult-onset glycogen storage disease type II. *Neurology*. 1999;52:851-853. https://pubmed.ncbi.nlm.nih.gov/10078739/

Beck M. Alglucosidase alfa: long term use in the treatment of patients with Pompe disease. *Ther Clin Risk Manag*. 2009;5:767-772. https://pubmed.ncbi.nlm.nih.gov/19816575/

Bernstein DL, et al. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. *Mol Genet Metab*. 2010;101:130-133. https://pubmed.ncbi.nlm.nih.gov/20638881/

Burrow TA, et al. Acute progression of neuromuscular findings in infantile Pompe disease. *Pediatr Neurol*. 2010;42:455-458. https://pubmed.ncbi.nlm.nih.gov/20472203/

Hagemans MLC, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. *Brain*. 2005;128:671-677. https://pubmed.ncbi.nlm.nih.gov/15659425/

Hagemans MLC, et al. Disease severity in children and adults with Pompe disease related to age and disease duration. *Neurology*. 2005;64:2139-2141. https://pubmed.ncbi.nlm.nih.gov/15985590/

Hahn SH, et al. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. *Genet Med*. 2018;20:1284-1294. https://pubmed.ncbi.nlm.nih.gov/29565424/

Hamdan MA, et al. Antenatal diagnosis of pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy. *J Inherit Metab Dis.* 2010;33(suppl 3):S333-S339. https://pubmed.ncbi.nlm.nih.gov/20821053/

Leslie N, Bailey L. Pompe disease. In: Adam MP, et al (eds). *GeneReviews [Internet]*. University of Washington, Seattle; 1993-2022. https://www.ncbi.nlm.nih.gov/books/NBK1261

Kishnani PS, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. *J Pediatr.* 2006;148:671-676. https://pubmed.ncbi.nlm.nih.gov/16737883/

Kishnani PS, et al. Pompe disease diagnosis and management guideline. *Genet Med.* 2006;8:267-288. https://pubmed.ncbi.nlm.nih.gov/16702877/

Kishnani PS, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology*. 2007;68:99-109. https://pubmed.ncbi.nlm.nih.gov/17151339/

Kishnani PS, et al. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. *Am J Med Genet Part C Semin Med Genet.* 2012;160C:1-7. https://pubmed.ncbi.nlm.nih.gov/22253049/

Koeberl DD, et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. *Mol Genet Metab*. 2011;103:107-112. https://pubmed.ncbi.nlm.nih.gov/21397538/

Continued →

Laforêt P, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 2000;55:1122-1128. https://pubmed.ncbi.nlm.nih.gov/11071489/

McDowell R, et al. Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. *Genet Med*. 2008;10:758-762. https://pubmed.ncbi.nlm.nih.gov/18813140/

McNamara ER, et al. Expanding our understanding of lower urinary tract symptoms and incontinence in adults with Pompe disease. *JIMD Rep*. 2015;20:5-10. https://pubmed.ncbi.nlm.nih.gov/25614307/

Mellies U, et al. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. *Neurology.* 2001;57:1290-1295. https://pubmed.ncbi.nlm.nih.gov/11591850/

Nicolino M, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. *Genet Med*. 2009;11:210-219. https://pubmed.ncbi.nlm.nih.gov/19287243/

Patel TT, et al. Basilar artery aneurysm: a new finding in classic infantile Pompe disease. *Muscle Nerve.* 2013;47:613-615. https://pubmed.ncbi.nlm.nih.gov/23401069/

Prakalapakorn SG, et al. Ocular and histologic findings in a series of children with infantile Pompe disease treated with enzyme replacement therapy. *J Pediatr Ophthalmol Strabismus*. 2014;51:355-362. https://pubmed.ncbi.nlm.nih.gov/25139343/

Prater SN, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. *Genet Med.* 2012;14:800-810. https://pubmed.ncbi.nlm.nih.gov/22538254/

Rairikar MV, et al. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant. *Mol Genet Metab.* 2017;122:99-107. https://pubmed.ncbi.nlm.nih.gov/28951071/

Slonim AE, et al. Identification of two subtypes of infantile acid maltase deficiency. *J Pediatr.* 2000;137:283-285. https://pubmed.ncbi.nlm.nih.gov/10931430/

Thurberg BL, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. *Lab Invest.* 2006;86:1208-1220. https://pubmed.ncbi.nlm.nih.gov/17075580/

van der Ploeg AT, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. *N Engl J Med.* 2010;362:1396-1406. https://pubmed.ncbi.nlm.nih.gov/20393176/

van der Ploeg AT, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. *Mol Genet Metab.* 2012;107:456-461. https://pubmed.ncbi.nlm.nih.gov/23031366/

Improving Disease Progression Outcomes with Advancing Therapeutics

Chien Y-H, et al. Pompe disease: early diagnosis and early treatment make a difference. *Pediatr Neonatol.* 2013;54:219-227. https://pubmed.ncbi.nlm.nih.gov/23632029/

Chien Y-H, et al. Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening. *JIMD Rep.* 2015;19:67-73. https://pubmed.ncbi.nlm.nih.gov/25681082/

Diaz-Manera J, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. *Lancet Neurol.* 2021;20:1012-1026. https://pubmed.ncbi.nlm.nih.gov/34800399/

Huggins E, et al. Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening. *Mol Genet Metab.* 2022;135:179-185. https://pubmed.ncbi.nlm.nih.gov/35123877/

Kishnani PS, Beckemeyer AA. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. *Pediatr Endocrinol Rev.* 2014;12(suppl 1):114-124. https://pubmed.ncbi.nlm.nih.gov/25345093/

Continued →

Kishnani PS, et al. Mini-COMET study: individual participant-level responses to treatment in patients with infantile-onset Pompe disease receiving repeated dose regimens of avalglucosidase alfa or alglucosidase alfa who were previously treated with alglucosidase alfa. *Mol Genet Metab.* 2021;132:S57-S58. https://www.sciencedirect.com/journal/molecular-genetics-and-metabolism/vol/132/suppl/S1?page=2

Kishnani PS, et al. The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: efficacy and safety results after 97 weeks. Presented at: 18th Annual WORLDSymposium; February 7-11, 2022; Abstract 153.

Kronn D, et al. Response to omalizumab in a 5 yr old patient with infantile onset Pompe disease (IOPD) with anaphylactoid reactions. 14th Annual World Symposium. February 5-9, 2018. Poster 198. https://worldsymposia.org/worldsymposium-2018-meeting-highlights/2018-poster-sessions/

Kronn D, et al. Mini-COMET study: safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥97 weeks in participants with infantile-onset Pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline. Presented at: 14th Annual WorldSymposium; February 5-9, 2018; Abstract 156.

Leslie N, Bailey L. Pompe disease. In: Adam MP, et al (eds). *GeneReviews [Internet]*. University of Washington, Seattle; 1993-2022. https://www.ncbi.nlm.nih.gov/books/NBK1261

Matern D, et al. Newborn screening for lysosomal storage disorders. *Semin Perinatol.* 2015;39:206-216. https://pubmed.ncbi.nlm.nih.gov/25891428/

Montagnese F, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. *J Neurol.* 2015;262:968-978. https://pubmed.ncbi.nlm.nih.gov/25673129/

Pena LDM, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. *Neuromuscul Disord.* 2019;29:167-186. https://pubmed.ncbi.nlm.nih.gov/30770310/

Schoser B, et al. Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study subgroup analyses. Presented virtually at: World Muscle Society 2021 Virtual Congress; September 20-24, 2021; Poster EP.196. https://ir.amicusrx.com/static-files/ae1b8d9a-bd14-4ba4-be06-1dbe191d59e0

Schoser B, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. *Lancet Neurol.* 2021;20:1027-1037. https://pubmed.ncbi.nlm.nih.gov/34800400/

Van der Beek NAME, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. *Neuromuscul Disord.* 2009;19:113-117. https://pubmed.ncbi.nlm.nih.gov/19084399/

Young SP, et al. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. *Am J Med Genet C Semin Med Genet*. 2012;160C:50-58. https://pubmed.ncbi.nlm.nih.gov/22252961/

Clinical Case Review and Discussion: Implementing New Therapies into Practice

Banugaria SG, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. *PLoS One*. 2013;8:e67052. https://pubmed.ncbi.nlm.nih.gov/23825616/

Banugaria SG, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. *Genet Med.* 2013;15:123-131. doi:10.1038/gim.2012.110

Continued →

Berger KI, et al. Pathophysiology of hypoventilation during sleep. *Sleep Med Clin*. 2014;9:289-300. doi:10.1016/j.jsmc.2014.05.014

Desai AK, et al. Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort. *Front Immunol.* 2020;11:1727. https://pubmed.ncbi.nlm.nih.gov/32849613/

Kazi ZB, et al. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. *Genet Med*. 2019;21:887-895. doi:10.1038/s41436-018-0270-7

Kishnani PS, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. *Mol Genet Metab.* 2016;117:66-83. https://pubmed.ncbi.nlm.nih.gov/26597321/

Kronn DF, et al. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum. *Pediatrics.* 2017;140(suppl 1):S24-S45. https://publications.aap.org/pediatrics/article/140/Supplement_1/S24/179262/Management-of-Confirmed-Newborn-Screened-Patients

Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. *Respir Med.* 2009;103:477–84. https://pubmed.ncbi.nlm.nih.gov/19131232/